ClicBio is establishing a new therapeutic category to address metabolic disease by targeting the hunger pathway rather than the satiety pathway. Our research has identified the CLIC1 protein as a unique molecular control switch governing food intake, specifically by regulating the hunger signals originating from AgRP neurons in the hypothalamus. In animal models of obesity, blocking CLIC1 leads to weight loss comparable to GLP-1 agonists that primarily target satiety. Drugs that were initially developed to treat heart failure and high blood pressure, were subsequently found to also block CLIC1. Notably, these drugs demonstrated an excellent safety profile in human testing. ClicBio has modified the scaffold of these drugs to improve CLIC1 selectivity, generating new chemical entities that will pave the way for an entirely novel treatment paradigm for obesity and metabolic disease.